<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403804</url>
  </required_header>
  <id_info>
    <org_study_id>14-1783</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02403804</nct_id>
  </id_info>
  <brief_title>Dietary Supplementation to Increase Serum Choline Levels</brief_title>
  <official_title>Dietary Supplementation to Increase Serum Choline Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to assess whether, in adult women during the luteal phase of their menstrual&#xD;
      cycle, supplementing their diet with either phosphatidylcholine or betaine increases their&#xD;
      serum choline levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated maternal serum free choline has the potential to improve fetal brain development .&#xD;
      However, in humans, choline can be metabolized by gut flora into two metabolites with adverse&#xD;
      outcomes: trimethylurea (which causes body odor) and Trimethylamine (TMA) which is then, once&#xD;
      absorbed, metabolized into Trimethylamine-N-Oxide (TMAO). There is some concern that TMAO may&#xD;
      be atherogenic and thus, if elevated over an extended period of time, may increase risk for&#xD;
      cardiac disease. Thus, while maternal choline supplementation may improve fetal brain&#xD;
      development, there is a potential for maternal adverse effects.&#xD;
&#xD;
      However, humans have an active choline metabolic pathway, and other components of the choline&#xD;
      metabolic pathway (e.g. phosphatidylcholine and betaine) may be interchangeable with choline&#xD;
      post absorption but are resistant to gut bacteria metabolism (i.e. serum TMA does not&#xD;
      increase). Thus, these other compounds would be expected to increase serum but with no impact&#xD;
      on TMA or trimethylurea levels. An initial study of phosphatidylcholine supplementation in&#xD;
      pregnant women was consistent with this hypothesis; infant offspring demonstrated improved&#xD;
      cerebral inhibition; while no adverse events were identified for either mother or infant.&#xD;
&#xD;
      Unfortunately, because of the lipid groups incorporated into phosphatidylcholine, its&#xD;
      molecular weight is high and reasonable doses require consuming several large capsules a day.&#xD;
      The study represents the first attempt to determine if betaine, an alternative compound&#xD;
      within the same metabolic pathway but with a much lower molecular weight, also increases&#xD;
      serum choline levels. As the first step, this proposal seeks to address this in non-pregnant&#xD;
      women. Specifically, the goals are to (a) assess whether changes in serum choline levels in&#xD;
      response to molar equivalent supplementation of phosphatidylcholine versus betaine are&#xD;
      similar, and (b) whether, for betaine, there is a dose response relationship between&#xD;
      supplementation dose and serum choline levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">September 29, 2015</completion_date>
  <primary_completion_date type="Actual">September 29, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in serum choline</measure>
    <time_frame>4 hours post supplement.- baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in serum choline</measure>
    <time_frame>2 hours post supplementation.- baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum choline</measure>
    <time_frame>6 hours post supplementation.- baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum choline</measure>
    <time_frame>8 hours post supplementation.- baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum choline</measure>
    <time_frame>10 hours post supplementation.- baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum choline</measure>
    <time_frame>12 hours post supplementation - baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum choline</measure>
    <time_frame>1 week post supplementation - baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.&#xD;
Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm&#xD;
Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm&#xD;
Week 3: Betaine anhydrous 1000 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Phosphatidylcholine</intervention_name>
    <description>Phosphatidylcholine 3600 mg qam and 2700 mg qpm</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Betaine (588 mg qam and 412 mg qpm)</intervention_name>
    <description>Betaine anhydrous 588 mg qam and 412 mg qpm</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>Trimethylglycine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Betaine (1000 mg BID)</intervention_name>
    <description>Betaine anhydrous 1000 mg BID</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>Trimethylglycine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. premenopausal&#xD;
&#xD;
          2. No nicotine use&#xD;
&#xD;
          3. No marijuana use&#xD;
&#xD;
          4. No illicit substance use&#xD;
&#xD;
          5. Weight &gt;= 90 pounds&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. self-reported body odor of unknown etiology&#xD;
&#xD;
          2. personal or family history of cystathionine beta synthase deficiency (homocystinuria)&#xD;
&#xD;
          3. personal or family history of trimethylaminuria, renal or liver disease, Parkinson's&#xD;
             disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camille Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health and Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randal G Ross, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Olincy, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dietary supplements</keyword>
  <keyword>serum choline</keyword>
  <keyword>women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

